For patients with recurrent prostate cancer, PET scanning with 18F-flotufolastat led to major changes in treatment for 80 percent of patients and 75 percent of patients with a changed treatment focus to watchful waiting had negative scans, according to new research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU).
Emerging research from the SPOTLIGHT trial suggests the PET radiotracer 18F-flotufolastat may have a significant impact on treatment changes for patients with recurrent prostate cancer.
In a study, recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, researchers reviewed treatment plans prior to and after 97 patients with recurrent prostate cancer had positron emission tomography (PET) scans with 18F-flotufolastat (Posluma, Blue Earth Diagnostics).
The study authors noted this subgroup in comparison to the overall SPOTLIGHT study population had comparable percentages of prostatectomy procedures, Gleason scores and median prostate-specific antigen (PSA) levels.
The researchers found that 89 percent of the subgroup cohort (86 of 97 patients) had treatment changes after PET imaging and major changes to management plans occurred in 78 patients (80 percent). The study authors also noted negative 18F-flotufolastat PET scans for 75 percent of patients whose management plans were revised to watchful waiting.
“Both positive and negative 18F-flotufolastat PET scans did influence patient management. … We believe that treatment based on visualization of 18F-flotufolastat avid lesions may facilitate improved management of recurrent lesions,” noted study author Przemyslaw Twardowski, M.D., the director of clinical research in urology and urologic oncology at the Saint John’s Cancer Institute at Providence St. John’s Health Center in Santa Monica, Calif.
The study findings also revealed that 18F-flotufolastat PET scans revealed distant/extrapelvic lesions for all 15 patients whose treatment was changed from salvage therapy to non-curative systemic therapy.
“Treatment based on visualization of 18F-flotufolastat-avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” added Dr. Twardowski.
Reference
1. Twardowski P. Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: data from the SPOTLIGHT study. Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO-GU, San Francisco, Calif. Poster available at https://conferences.asco.org/gu/abstracts . Accessed January 25, 2024.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
MRI-Based Deep Learning Algorithm Shows Comparable Detection of csPCa to Radiologists
May 8th 2024In a study involving over 1,000 visible prostate lesions on biparametric MRI, a deep learning algorithm detected 96 percent of clinically significant prostate cancer (csPCa) in comparison to a 98 percent detection rate for an expert genitourinary radiologist.
Study Finds High Concordance Between AI and Radiologists for Cervical Spine Fractures on CT
May 6th 2024Researchers found a 98.3 percent concordance between attending radiology reports and AI assessments for possible cervical spine fractures on CT, according to new research presented at the 2024 ARRS Annual Meeting.